Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED (PROCOVAXED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05142332
Recruitment Status : Not yet recruiting
First Posted : December 2, 2021
Last Update Posted : December 2, 2021
Sponsor:
Collaborators:
Duke University
Thomas Jefferson University
University of Washington
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
The goal of this research is to increase COVID-19 and influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients). Toward this goal we will conduct one on one interviews and focus groups with ED Usual Source of Care Patients and community partners and produce trusted messaging informational platforms (PROmotion of COvid-19 VA(X)ccination in the Emergency Department - PROCOVAXED) that will address barriers to COVID-19 and influenza vaccination, especially vaccine hesitancy. We will then conduct a cluster-randomized, controlled trial of PROCOVAXED platforms in six EDs to determine whether their implementation is associated with greater COVID-19 and influenza vaccine acceptance and uptake in ED Usual Source of Care Patients.

Condition or disease Intervention/treatment Phase
Covid-19 Vaccine Influenza Vaccine Other: Covid-19 vaccine education materials Not Applicable

Detailed Description:

Our preliminary work research at 15 ED sites across the US indicates that ED Usual Source of Care patients have particular health care access barriers, needs, and perceptions about vaccines (vaccine hesitancy) that require specific review beyond traditional (non-ED user) community engagement techniques. To gain insight about messaging that effectively addresses these barriers, needs, and perceptions, we will conduct one on one interviews and focus group meetings with ED Usual Source of Care Patients and community partners.

At five safety net EDs (Zuckerberg San Francisco General, Thomas Jefferson University Hospital [Philadelphia], Methodist Hospital [Philadelphia], Harborview Medical Center [Seattle], and Duke University Medical Center [Durham, NC], we will conduct a cluster-randomized, controlled trial of implementation of PROCOVAXED platforms, with COVID-19 and influenza vaccine acceptance rates on post-intervention ED surveys as the primary outcomes. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with increased acceptance of COVID-19 and influenza vaccines in ED patients.

One month after subjects' index ED visit enrollment in our PROCOVAXED implementation trial we will conduct electronic health record review and phone follow-up surveys to determine ED patient uptake (receipt) of COVID-19 and influenza vaccines. Hypothesis: Implementation of PROCOVAXED platforms in EDs will be associated with greater COVID-19 and influenza vaccine uptake in ED patients.

We will conduct a cluster-randomized, controlled trial (RCT) of implementation of our PROCOVAXED platforms in 5 high-volume, safety net hospital EDs, testing two hypotheses that implementation of PROCOVAXED platforms will be associated with increased acceptance and uptake of COVID-19 and influenza vaccines in ED USCARE patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Cluster Randomized Trial: Intervention arm is delivery of Covid vaccine messaging Non-intervention arm is usual care.
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: PROmotion of COvid-19 VA(X)Ccination in the Emergency Department - PROCOVAXED
Estimated Study Start Date : December 6, 2021
Estimated Primary Completion Date : April 30, 2024
Estimated Study Completion Date : April 30, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention Arm
Covid vaccine educational intervention
Other: Covid-19 vaccine education materials
videos and flyers containing Covid-19 vaccine educational information

No Intervention: Non-interventional Arm
Usual care



Primary Outcome Measures :
  1. Covid-19 Vaccine uptake [ Time Frame: within one month of intervention ]
    participant update of Covid-19 vaccine



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults (>18 years of age) patients who have received care at the participating sites Emergency Department and have not yet received a COVID-19 vaccine

Exclusion Criteria:

  • major trauma patients
  • patients transferred from another hospital, chronic care facility, nursing home or hospice,
  • patients unable to participate in an interview because of intoxication, altered mental status or critical illness
  • incarcerated patients
  • patients on psychiatric holds
  • patients who have received a COVID-19 vaccine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05142332


Contacts
Layout table for location contacts
Contact: Robin Kemball, MPH 415-509-9842 robin.kemball@ucsf.edu
Contact: Virginia Chan virginiga.chan@ucsf.edu

Locations
Layout table for location information
United States, California
San Francisco General Hospital ICU
San Francisco, California, United States, 94110
Sponsors and Collaborators
University of California, San Francisco
Duke University
Thomas Jefferson University
University of Washington
Investigators
Layout table for investigator information
Principal Investigator: Robert Rodriguez, MD University of California, San Francisco
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT05142332    
Other Study ID Numbers: 21-34004
First Posted: December 2, 2021    Key Record Dates
Last Update Posted: December 2, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Emergencies
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes